Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies

被引:66
作者
Sauty, A
Rochat, T
Schoch, OD
Hamacher, J
Kurt, AM
Dayer, JM
Nicod, LP [1 ]
机构
[1] Univ Hosp Geneva, Div Pneumol, Dept Internal Med, CH-1211 Geneva 14, Switzerland
[2] Univ Hosp Geneva, Dept Pathol, Geneva, Switzerland
[3] St Gallen Hosp, Dept Internal Med, Div Immunol & Allergy, St Gallen, Switzerland
[4] St Gallen Hosp, Dept Internal Med, St Gallen, Switzerland
关键词
anti-Jo-1; CD8+ lymphocyte; inflammatory myositis; interstitial lung disease;
D O I
10.1183/09031936.97.10122907
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Interstitial lung disease (ILD) is a complication of polymyositis (PM) and dermatomyositis (DM), It often manifests itself in association with myositis-specific antisynthetase autoantibodies, among which anti-Jo-1 antibodies are the most commonly encountered. In contrast, ILD associated with anti-Jo-1 antibodies without muscle involvement is rare and not well characterized, We report four patients presenting with ILD associated with anti-Jo-1 antibodies, Histological findings of transbronchial biopsies disclosed a pattern consistent with nonspecific interstitial pneumonitis, a CD8+ lymphocytosis was found in bronchoalveolar lavage, Only one of these patients developed an "antisynthetase syndrome" with PM, after nearly 2 yrs of severe ILD, The clinical conditions of all four cases showed stabilization or improvement when cyclosporine was added to their immunosuppressive treatment, These cases confirm that a CD8+ lymphocytic interstitial lung disease may be the first, and sole manifestation of autoimmune disease associated with anti-Jo-1 antibodies. Furthermore, they suggest that this form of interstitial lung disease apparently has a poor response to steroids and cytotoxic drugs, but may respond to moderate doses of cyclosporine and azathioprine in addition to low doses of steroids.
引用
收藏
页码:2907 / 2912
页数:6
相关论文
共 30 条
[1]  
ALJANADI M, 1989, J RHEUMATOL, V16, P1592
[2]   ADVERSE IMPACT OF INTERSTITIAL PULMONARY FIBROSIS ON PROGNOSIS IN POLYMYOSITIS AND DERMATOMYOSITIS [J].
ARSURA, EL ;
GREENBERG, AS .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 1988, 18 (01) :29-37
[3]  
*BAL COOP GROUP ST, 1990, AM REV RESPIR DIS, V141, pS199
[4]   ANTI-JO-1 ANTIBODY - A MARKER FOR MYOSITIS WITH INTERSTITIAL LUNG-DISEASE [J].
BERNSTEIN, RM ;
MORGAN, SH ;
CHAPMAN, J ;
BUNN, CC ;
MATHEWS, MB ;
TURNERWARWICK, M ;
HUGHES, GRV .
BRITISH MEDICAL JOURNAL, 1984, 289 (6438) :151-152
[5]   ANTI-JO-1 SYNDROME PRESENTING AS CRYPTOGENIC ORGANIZING PNEUMONIA [J].
CHAN, WM ;
IP, M ;
LAU, CS ;
WANG, E ;
PEH, WCG .
RESPIRATORY MEDICINE, 1995, 89 (09) :639-641
[6]  
CHMIEL JF, 1995, J RHEUMATOL, V22, P762
[7]   ADULT-RESPIRATORY-DISTRESS-SYNDROME IN POLYMYOSITIS PATIENTS WITH THE ANTI-JO-1 ANTIBODY [J].
CLAWSON, K ;
ODDIS, CV .
ARTHRITIS AND RHEUMATISM, 1995, 38 (10) :1519-1523
[8]  
Dalakas Marinos C., 1994, Current Opinion in Rheumatology, V6, P595, DOI 10.1097/00002281-199411000-00008
[9]   CYCLOSPORINE-A TREATMENT OF DERMATOMYOSITIS [J].
DANKO, K ;
SZEGEDI, G .
ARTHRITIS AND RHEUMATISM, 1991, 34 (07) :933-934
[10]  
DORTHO MPF, 1991, REV PNEUMOL CLIN, V47, P29